Updates are available Correction dated 2025-03-20
Click to view Correction: https://doi.org/10.1038/s41467-025-57553-8
-
Authors
Huhn, Anna
Nissley, Daniel
Wilson, Daniel B.
Kutuzov, Mikhail A. https://orcid.org/0000-0003-3386-4350
Donat, Robert https://orcid.org/0000-0003-3432-5690
Tan, Tiong Kit https://orcid.org/0000-0001-8746-8308
Zhang, Ying
Barton, Michael I. https://orcid.org/0000-0002-9263-6481
Liu, Chang
Dejnirattisai, Wanwisa
Supasa, Piyada
Mongkolsapaya, Juthathip https://orcid.org/0000-0003-3416-9480
Townsend, Alain
James, William https://orcid.org/0000-0002-2506-1198
Screaton, Gavin https://orcid.org/0000-0002-3549-4309
van der Merwe, P. Anton https://orcid.org/0000-0001-9902-6590
Deane, Charlotte M. https://orcid.org/0000-0003-1388-2252
Isaacson, Samuel A. https://orcid.org/0000-0002-7543-8619
Dushek, Omer https://orcid.org/0000-0001-5847-5226
- License Information
-
More Information
Article History
Received: 21 May 2024
Accepted: 22 November 2024
First Online: 2 January 2025
Change Date: 20 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-57553-8
Competing interests
: G.R.S. is on the GSK Vaccines Scientific Advisory Board, a founder shareholder of RQ Biotechnology, and a Jenner investigator. Oxford University holds intellectual property related to the Oxford-AstraZeneca vaccine. The remaining authors declare no competing interests.
